Programmed death ligand 1 (PD-L1) is the principal ligand of programmed death 1 (PD-1), a coinhibitory receptor that can be constitutively expressed or induced in myeloid, lymphoid, normal epithelial cells and in cancer. A key immune checkpoint is triggered when PD-1 (programmed cell death protein 1) engages its ligand PD-L1. As a result of this interaction, T cell activation is attenuated and an active immune response is prevented.
This mechanism is often co-opted by tumors. PD-L1 is upregulated in several tumor types and contributes to the malignancy of these cancers by interacting with PD-1 and inhibiting T cell activation. In this way, the tumors avoid detection and destruction by the immune system. Accordingly, PD-1 and PD-L1 have garnered much attention for their roles in tumor immunology and as immune-based therapeutic targets.
Human Tonsil Tissues
PDL1, PD-L1, CD274, B7-H1, B7H1
Cancer Drug Targets
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Immunohistochemical analysis of paraffin-embedded human tonsil tissue labeling PD-L1 with HCB-Y128 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) ready to use. epithelial portion of tonsillar crypts is observed as strong positive staining, follicular macrophages in the germinal center are observed as weak to medium positive staining, endothelial cells, fibroblasts, and surface epithelial cells are all observed as negative staining. Counter stained with Hematoxylin. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
Immunohistochemical analysis of paraffin-embedded human cancer tissue labeling PD-L1 with HCB-Y128 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) ready to use. Membranous staining on human cancer tumor cells is observed. Counter stained with Hematoxylin. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.